Compare STKL & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKL | BCYC |
|---|---|---|
| Founded | 1973 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 769.4M | 360.7M |
| IPO Year | 1999 | 2019 |
| Metric | STKL | BCYC |
|---|---|---|
| Price | $6.50 | $5.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $7.50 | ★ $13.90 |
| AVG Volume (30 Days) | ★ 1.2M | 584.2K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 186.67 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $817,715,000.00 | N/A |
| Revenue This Year | $6.84 | N/A |
| Revenue Next Year | $33.58 | N/A |
| P/E Ratio | $49.92 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $3.32 | $4.24 |
| 52 Week High | $6.94 | $9.55 |
| Indicator | STKL | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 68.77 | 54.14 |
| Support Level | $6.43 | $5.03 |
| Resistance Level | $6.52 | $5.90 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 58.33 | 81.08 |
SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own proprietary brands, including SOWN, Dream, and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut, and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada, and Others, out of which it derives maximum revenue from U.S.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.